BR112022027038A2 - Vacinas de replicon de rna contra hbv - Google Patents
Vacinas de replicon de rna contra hbvInfo
- Publication number
- BR112022027038A2 BR112022027038A2 BR112022027038A BR112022027038A BR112022027038A2 BR 112022027038 A2 BR112022027038 A2 BR 112022027038A2 BR 112022027038 A BR112022027038 A BR 112022027038A BR 112022027038 A BR112022027038 A BR 112022027038A BR 112022027038 A2 BR112022027038 A2 BR 112022027038A2
- Authority
- BR
- Brazil
- Prior art keywords
- hbv
- antigens
- vaccines against
- rna replicon
- against hbv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
VACINAS DE REPLICON DE RNA CONTRA HBV. A presente invenção refere-se a moléculas de ácido nucleico que codificam os antígenos de superfície de vírus da hepatite B (HBV), antígenos de núcleo de HBV, e antígenos de HBV polimerase e combinações relacionadas. Também descritos são vetores, tal como, plasmídeos de DNA ou vetores virais, e replicons de RNA, expressando os antígenos de HBV, e composições farmacêuticas contendo os vetores de expressão. Métodos de indução de uma resposta imune contra HBV ou tratamento de uma doença induzida por HBV, particularmente em indivíduos com infecção crônica por HBV, usando as composições farmacêuticas da invenção também são descritos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063049400P | 2020-07-08 | 2020-07-08 | |
US202163144051P | 2021-02-01 | 2021-02-01 | |
PCT/EP2021/068879 WO2022008613A1 (en) | 2020-07-08 | 2021-07-07 | Rna replicon vaccines against hbv |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022027038A2 true BR112022027038A2 (pt) | 2023-01-24 |
Family
ID=77104021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022027038A BR112022027038A2 (pt) | 2020-07-08 | 2021-07-07 | Vacinas de replicon de rna contra hbv |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220016237A1 (pt) |
EP (1) | EP4178613A1 (pt) |
JP (1) | JP2023533528A (pt) |
KR (1) | KR20230050328A (pt) |
CN (1) | CN116367854A (pt) |
AU (1) | AU2021303478A1 (pt) |
BR (1) | BR112022027038A2 (pt) |
CA (1) | CA3188801A1 (pt) |
IL (1) | IL299571A (pt) |
TW (1) | TW202216190A (pt) |
WO (1) | WO2022008613A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016306275A1 (en) | 2015-08-07 | 2018-02-08 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for Hepatitis B virus infection |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
TW202245809A (zh) * | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
KR100427786B1 (ko) | 1997-04-03 | 2004-04-30 | 일렉트로우펙트 에이에스 | 약물과 핵산의 골격 근육 내 주입 장치 및 방법 |
US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
DE69826124T3 (de) | 1997-06-30 | 2007-10-11 | Institut Gustave Roussy | Verabreichung der nukleinsäure in den quergestreiften muskel |
EP2428249B1 (en) | 1998-07-13 | 2015-10-07 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
DE60014489T3 (de) | 1999-05-17 | 2010-08-12 | Crucell Holland B.V. | Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten |
US7468181B2 (en) | 2002-04-25 | 2008-12-23 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
IL154712A0 (en) | 2000-11-23 | 2003-10-31 | Bavarian Nordic As | Modified vaccinia ankara virus variant |
EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
JP4495588B2 (ja) | 2002-04-25 | 2010-07-07 | クルセル ホランド ベー ヴェー | 安定なアデノウイルスベクターおよびその増殖方法 |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
LT2163260T (lt) | 2004-01-23 | 2017-06-26 | Msd Italia S.R.L. | Šimpanzės adenoviruso vakcinos nešikliai |
EP3466483A1 (en) | 2004-03-08 | 2019-04-10 | Ichor Medical Systems Inc. | Improved apparatus for electrically mediated delivery of therapeutic agents |
ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
DK2066399T3 (en) | 2006-10-17 | 2019-01-21 | Inovio Pharmaceuticals Inc | Electroporation devices and methods for using them for the electroporation of cells in mammals |
JP5749494B2 (ja) | 2008-01-02 | 2015-07-15 | テクミラ ファーマシューティカルズ コーポレイション | 核酸の送達のための改善された組成物および方法 |
AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
AU2009303345B2 (en) | 2008-10-09 | 2015-08-20 | Arbutus Biopharma Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
HUE037082T2 (hu) | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
US20120101148A1 (en) | 2009-01-29 | 2012-04-26 | Alnylam Pharmaceuticals, Inc. | lipid formulation |
WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
SG172935A1 (en) | 2009-02-02 | 2011-08-29 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
JP5769701B2 (ja) | 2009-05-05 | 2015-08-26 | テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation | 脂質組成物 |
DK2440183T3 (en) | 2009-06-10 | 2018-10-01 | Arbutus Biopharma Corp | Improved lipid formulation |
NZ605079A (en) | 2010-06-03 | 2015-08-28 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
LT2590676T (lt) | 2010-07-06 | 2016-10-25 | Glaxosmithkline Biologicals Sa | Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms |
EA029504B1 (ru) | 2010-12-14 | 2018-04-30 | Дзе Гавермент Оф Дзе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Дзе Секретэри Оф Дзе Департмент Оф Хелт Энд Хьюмэн Сервисиз | Способ индуцирования иммунного ответа против филовирусного антигена у пациента с использованием аденовирусов серотипа 26 и серотипа 35 |
TR201900264T4 (tr) | 2011-08-31 | 2019-02-21 | Glaxosmithkline Biologicals Sa | İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar. |
US9352042B2 (en) | 2012-02-24 | 2016-05-31 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
SI3766916T1 (sl) | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc. | Formulacije novih lipidov in lipidnih nanodelcev za dostavo nukleinskih kislin |
WO2017004143A1 (en) | 2015-06-29 | 2017-01-05 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
CN113636947A (zh) | 2015-10-28 | 2021-11-12 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
WO2017117528A1 (en) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US9834510B2 (en) | 2015-12-30 | 2017-12-05 | Arcturus Therapeutics, Inc. | Aromatic ionizable cationic lipid |
WO2017121791A1 (en) * | 2016-01-12 | 2017-07-20 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Means and methods for treating hbv |
KR102535764B1 (ko) | 2016-03-28 | 2023-05-30 | 아이커 메디칼 시스템스 인코포레이티드 | 치료제를 전달하기 위한 장치 |
CN110073002A (zh) | 2016-10-17 | 2019-07-30 | 合成基因组公司 | 重组病毒复制子体系及其用途 |
WO2018106615A2 (en) | 2016-12-05 | 2018-06-14 | Synthetic Genomics, Inc. | Compositions and methods for enhancing gene expression |
WO2018119163A1 (en) | 2016-12-21 | 2018-06-28 | Payne Joseph E | Ionizable cationic lipid for rna delivery |
US10383952B2 (en) | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
EP3668833A1 (en) | 2017-08-16 | 2020-06-24 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
CA3073018A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
-
2021
- 2021-07-07 AU AU2021303478A patent/AU2021303478A1/en active Pending
- 2021-07-07 TW TW110124915A patent/TW202216190A/zh unknown
- 2021-07-07 KR KR1020237004630A patent/KR20230050328A/ko unknown
- 2021-07-07 IL IL299571A patent/IL299571A/en unknown
- 2021-07-07 BR BR112022027038A patent/BR112022027038A2/pt unknown
- 2021-07-07 CN CN202180055052.7A patent/CN116367854A/zh active Pending
- 2021-07-07 CA CA3188801A patent/CA3188801A1/en active Pending
- 2021-07-07 JP JP2023501042A patent/JP2023533528A/ja active Pending
- 2021-07-07 WO PCT/EP2021/068879 patent/WO2022008613A1/en active Application Filing
- 2021-07-07 EP EP21746660.6A patent/EP4178613A1/en active Pending
- 2021-07-08 US US17/370,337 patent/US20220016237A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230050328A (ko) | 2023-04-14 |
CA3188801A1 (en) | 2022-01-13 |
JP2023533528A (ja) | 2023-08-03 |
TW202216190A (zh) | 2022-05-01 |
CN116367854A (zh) | 2023-06-30 |
IL299571A (en) | 2023-02-01 |
US20220016237A1 (en) | 2022-01-20 |
WO2022008613A1 (en) | 2022-01-13 |
AU2021303478A1 (en) | 2023-02-16 |
EP4178613A1 (en) | 2023-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022027038A2 (pt) | Vacinas de replicon de rna contra hbv | |
PH12020550924A1 (en) | Heptatitis b virus (hbv) vaccines and uses thereof | |
EA202091513A1 (ru) | Вакцины против вируса гепатита b (hbv) и их применение | |
BR112017014219A2 (pt) | vacinas à base de nanopartículas multivalentes | |
Shum et al. | Aptamer-based therapeutics: new approaches to combat human viral diseases | |
BR112018009032A8 (pt) | vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
WO2009143524A3 (en) | Nanoemulsion vaccines | |
BR112017000320A2 (pt) | métodos para o tratamento de infecções virais de hepatite b e hepatite d | |
BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
CO2019003675A2 (es) | Meganucleasas diseñadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b. | |
Omatsu et al. | Induction and sequencing of Rousette bat interferon α and β genes | |
BR112018007121A2 (pt) | anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv | |
Dance | Coronavirus vaccines get a biotech boost | |
CO6541529A2 (es) | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos | |
AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
BR112017024283A2 (pt) | vacinas contra a dengue | |
BR112019003181A2 (pt) | composição para aumentar uma resposta imune em animal, método para induzir uma resposta imune protetora em um sujeito, e, uso da composição na preparação de um medicamento. | |
Morozova | The problems and perspectives of prevention, diagnostic and treatment of tick-borne encephalitis | |
AR113961A1 (es) | Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas | |
Pushko et al. | Experimental DNA-launched live-attenuated vaccines against yellow fever | |
Berkhout et al. | Gene therapy for HIV and chronic infections | |
Sepulveda et al. | Natural killer cells and the innate immune system in infectious pathology |